Mobile Trading

MANKIND PHARMA LTD.

NSE : MANKINDBSE : 543904ISIN CODE : INE634S01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE2289.05-33.7 (-1.45 %)
PREV CLOSE ( ) 2322.75
OPEN PRICE ( ) 2323.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 5095
TODAY'S LOW / HIGH ( )2282.85 2325.10
52 WK LOW / HIGH ( )1910.1 3050
Select year
ParticularsMar2024Mar2023Mar2022Mar2021Mar2020
Operational & Financial Ratios
   Earnings Per Share (Rs)47.7532.0035.7831.5925.72
   CEPS(Rs)58.4140.8340.4335.2528.84
   DPS(Rs)0.000.000.000.003.10
   Book NAV/Share(Rs)233.15185.61153.65117.8887.00
   Tax Rate(%)19.0721.6326.4223.5626.54
Margin Ratios
   Core EBITDA Margin(%)23.5920.8924.6625.5023.68
   EBIT Margin(%)22.6418.8625.2126.4923.95
   Pre Tax Margin(%)22.3218.3524.4726.1623.57
   PAT Margin (%)18.0614.3818.0020.0017.31
   Cash Profit Margin (%)21.7617.9620.0721.8418.94
Performance Ratios
   ROA(%)18.0113.9418.8322.7923.19
   ROE(%)23.1519.2726.7231.5133.48
   ROCE(%)28.3823.4933.9639.9743.57
   Asset Turnover(x)1.000.971.051.141.34
   Sales/Fixed Asset(x)1.931.922.523.123.33
   Working Capital/Sales(x)2.423.704.532.563.89
Efficiency Ratios
   Fixed Capital/Sales(x)0.520.520.400.320.30
   Receivable days24.1819.3316.2524.3222.48
   Inventory Days51.8065.3166.5758.7851.46
   Payable days120.04130.57131.38144.73127.01
Valuation Parameters
   PER(x)48.110.000.000.000.00
   PCE(x)39.330.000.000.000.00
   Price/Book(x)9.850.000.000.000.00
   Yield(%)0.00
   EV/Net Sales(x)8.81-0.030.06-0.07-0.04
   EV/Core EBITDA(x)32.31-0.120.23-0.23-0.16
   EV/EBIT(x)37.39-0.150.25-0.25-0.17
   EV/CE(x)9.52-0.030.06-0.07-0.05
   M Cap / Sales8.900.000.000.000.00
Growth Ratio
   Net Sales Growth(%)18.1212.4425.225.8317.91
   Core EBITDA Growth(%)38.76-7.1420.1417.5458.34
   EBIT Growth(%)41.78-15.6018.7817.2359.00
   PAT Growth(%)48.26-9.8612.3722.4373.00
   EPS Growth(%)49.23-10.5813.2822.8178.11
Financial Stability Ratios
   Total Debt/Equity(x)0.020.020.140.050.04
   Current Ratio(x)3.102.321.682.872.25
   Quick Ratio(x)2.361.521.012.051.54
   Interest Cover(x)69.4637.5234.0280.9662.87
   Total Debt/Mcap(x)0.00

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.